Month: May 2023

Cellebrite and The Exodus Road Provide Digital Intelligence Technology to the National Bureau of Investigations Anti-Human Trafficking Division in the Philippines

Written by Customer Service on May 16, 2023. Posted in Public Companies.

As the digital world enables the spread of human trafficking and exploitation, Cellebrite empowers law enforcement with advanced digital intelligence in support of their efforts to outsmart online criminal activity and secure justice for survivors of exploitation. PETAH TIKVA, Israel and TYSONS CORNER, Va. and COLORADO SPRINGS, Colo., May 16, 2023 (GLOBE NEWSWIRE) — Cellebrite DI Ltd. (Nasdaq: CLBT), a global leader in Digital Intelligence (DI) solutions for the public and private sectors, and The Exodus Road, an international nonprofit organization disrupting human trafficking, announced today that they are providing digital intelligence technology to ensure the National Bureau of Investigations (NBI) Anti-Human Trafficking Division in the Philippines has the capacity to accelerate justice in cases of exploitation. Cellebrite...

Skyward Specialty Adds Anthony J. Kuczinski to Board of Directors

Written by Customer Service on May 16, 2023. Posted in Public Companies.

HOUSTON, May 16, 2023 (GLOBE NEWSWIRE) — Skyward Specialty Insurance Group Inc.TM (NASDAQ: SKWD) (“Skyward Specialty” or “the Company”), a leader in the specialty property and casualty market, is pleased to announce the addition of Anthony J. Kuczinski to its Board of Directors effective August 1, 2023. With more than 38 years of industry expertise, Kuczinski adds unmatched knowledge and experience to the Skyward Specialty board. Widely recognized through the insurance industry for his ability to drive long-term profitable growth, Kuczinski spent 34 years at Munich Re, serving as President and Chief Executive Officer for 15 years of Munich Reinsurance US Holdings. In addition to his storied career at Munich Re, Kuczinski has assumed numerous leadership positions on the boards of key industry organizations,...

QSAM Biosciences and RLS Announce Clinical and Commercial Supply Agreement for Promising Clinical-Stage Metastatic and Primary Bone Cancer Treatment, CycloSam®

Written by Customer Service on May 16, 2023. Posted in Public Companies.

Partnership is Latest in Series of RLS Efforts to Expand Industry-Leading CDMO Business and Clinical Trial Capability with Radiopharmaceutical Partners Across U.S. Austin, TX and Lake Zurich, IL, May 16, 2023 (GLOBE NEWSWIRE) — QSAM Biosciences, Inc. (OTCQB: QSAM), a clinical stage biotechnology company developing next-generation therapeutic radiopharmaceuticals, and RLS (USA) Inc., the third-largest nuclear medicine pharmacy network in the U.S., announced today a commercial supply and clinical dose preparation agreement for the therapeutic radiopharmaceutical drug candidate CycloSam® (Samarium-153 DOTMP), a promising clinical-stage treatment for metastatic and primary bone cancer in adults and children. QSAM is actively enrolling patients with metastatic bone cancer in a Phase I clinical trial for CycloSam® across three clinical...

Ikano Bank Digitalizes with NETSOL’s NFS Ascent & Digital Platforms

Written by Customer Service on May 16, 2023. Posted in Public Companies.

Alongside Northern Europe, NFS Ascent is already live in North America, Asia-Pacific and the UK ENCINO, Calif., May 16, 2023 (GLOBE NEWSWIRE) — NETSOL Technologies, Inc. (Nasdaq: NTWK), a global business services and enterprise application solutions provider, announced the go-live of its next-generation solution NFS Ascent for Ikano Bank – a Swedish bank operating across the Nordic and European regions. NETSOL’s NFS Ascent and suite of digital solutions are being implemented on the Cloud to support Ikano Bank’s lending to businesses. “The partnership with Ikano Bank is a significant project for NETSOL Europe representing the largest multi-country roll-out of our premier platform NFS Ascent. This engagement contributes to a multi-million-euro partnership for the Nordic region and beyond,” said Asad Ghauri, President Asia-Pacific...

SAB Biotherapeutics Provides Company Update for Q1 2023 Financial Results

Written by Customer Service on May 16, 2023. Posted in Earnings Releases And Operating Results.

SIOUX FALLS, S.D., May 16, 2023 (GLOBE NEWSWIRE) — SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human immunoglobulins (hIgG), also known as fully-human polyclonal antibodies, without the need for human donors, yesterday reported financial results for the first quarter ended March 31, 2023, and provided a company update. “Our first quarter 2023 results demonstrate that we continue to execute on our strategy to develop and deliver powerful immunotherapeutic treatments to patients with significant unmet needs. We recently announced Breakthrough Therapy Designation and Fast Track designation for SAB-176 from the FDA further validating the potential of our immunotherapy platform to treat a wide...

NNN REIT, Inc. (NYSE:NNN) President and CEO Steve Horn Interviewed by Advisor Access

Written by Customer Service on May 16, 2023. Posted in Dividend Reports And Estimates.

NNN REIT (NYSE:NNN): 33 Years of Annual Dividend Increases SAN FRANCISCO, May 16, 2023 (GLOBE NEWSWIRE) — NNN REIT, Inc. (NYSE: NNN), a real estate investment trust, invests primarily in high-quality retail properties subject to long-term leases. As of March 31, 2023, the company owned 3,449 properties in 49 states with a gross leasable area of approximately 35.3 million square feet and with a weighted average remaining lease term of 10.3 years. Click to view the NNN REIT Fact Sheet Click to view the NNN REIT Investor Presentation Click to visit the NNN REIT Website President and CEO Steve Horn talks to Advisor Access about the company’s strategy that has led to 33 successive years of dividend growth. Advisor Access: Your company announced its name change to NNN REIT, Inc. What brought about the change? Steve Horn: I’m excited...

Unicycive Announces First Quarter 2023 Financial Results and Provides Business Update

Written by Customer Service on May 16, 2023. Posted in Earnings Releases And Operating Results.

Closed on previously announced transformational fundraising that included $30 million financing upfront with up to an additional $100 million tied to the satisfaction of milestones Continued progress with plan to file New Drug Application with the U.S. Food and Drug Administration in Q3 2023, with the potential for approval and launch in 2024 LOS ALTOS, Calif., May 16, 2023 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the first quarter ended March 31, 2023 and provided a business update. “The first quarter of 2023 was transformational for Unicycive and positions us for continued success throughout the balance of the year and beyond as we expect...

REPEAT – Cleantech Power Corp. Enters Into Non-Binding Letter of Intent to Acquire Combined Heat and Power Assets

Written by Customer Service on May 16, 2023. Posted in Mergers And Acquisitions.

TORONTO, May 16, 2023 (GLOBE NEWSWIRE) — Cleantech Power Corp. (NEO: PWWR) (OTCQB: PWWRF) (Frankfurt: E43, WKN: A3EEHV) (“PWWR” or the “Company”), a diversified investment platform developing affordable, renewable, and reliable power and cleantech, is pleased to announce that the Company has entered into a non-binding letter of intent (the “Letter of Intent”) with an arm’s length third party to acquire, directly and indirectly, certain operating combined heat and power and other assets (the “CHP Assets”) located in North America (the “Potential Transaction”). Pursuant to the Letter of Intent, the Company may acquire the CHP Assets by making two payments. The first payment relates to CHP Assets which are past commercial operation and will consist of a payment of approx. $7.5 million (the “COD Payment”). The COD Payment will be made...

Avicanna Reports Q1 2023 Financial Statement

Written by Customer Service on May 16, 2023. Posted in Earnings Releases And Operating Results.

TORONTO, May 16, 2023 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, is pleased announce the filing of interim financial statements for the three-month period ending March 31, 2023 (“Q1 2023”). Aras Azadian, CEO stated, “We are pleased to report on our continued progress related to our optimization of operations in addition to Canadian commercialization during the first quarter of 2023. We have achieved operational efficiencies that enables us to now focus on scaling our revenues which we expect to be growing during 2023 through our Canadian and international efforts.” Q1 2023 highlights:Shoppers Drug Mart partnership to transition Medical...

Salona Global Closes Acquisition of Arrowhead Medical, Provides Update on Biodex Integration; Posts First Quarter Results with Positive Adjusted EBITDA, 23% Annual Revenue Growth and 27% Growth in Annual Gross Profits, Improved Quarter-over-Quarter Gross Profit from 33.1% to 38%

Written by Customer Service on May 16, 2023. Posted in Earnings Releases And Operating Results.

SAN DIEGO, May 16, 2023 (GLOBE NEWSWIRE) — Salona Global Medical Device Corporation (“Salona Global”, “SGMD” or the ‎‎“Company”) (TSXV:SGMD) today announced it closed its acquisition of Arrowhead Medical, LLC (“Arrowhead”), a recovery science medical device sales and distribution business expected to add $4.0 million in annual revenue to the Company, with an estimated 32% in gross profit. The Company also reported financial highlights for the first quarter of 2023, ending March 31, 2023, and provided details for its earnings call scheduled for 5pm EST today. Acquisition of Arrowhead and Biodex Integration Update The Company closed its acquisition of Arrowhead, a recovery science medical device sales and distribution business, on May 15, 2023. This addition to Salona Global is projected to add $4.0 million in revenue annually with...

M	T	W	T	F	S	S
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31

Month: May 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals